Introduction
============

Despite a worldwide decline in incidence and mortality in the last 60 years, gastric cancer remains the fourth most common type of cancer and the second most frequent cause of cancer mortality. Gastric cancer continues to be a major health concern due to the slow decrease in incidence in Asia and the high mortality from diagnosed gastric carcinomas in the West, even though advanced diagnostic and operative techniques are widely applied in clinical practice ([@b1-ol-06-05-1277],[@b2-ol-06-05-1277]). Increased understanding of the proliferative and apoptotic changes in gastric cancer, particularly the identification of novel biomarkers for cancer diagnosis and targets for treatment, may result in the improvement of diagnosis, treatment and prevention.

Ki-67 antigen (also known as MKI67) is in the nuclei of cells in the G~1~, S, G~2~ and mitosis phases of the cell cycle and is associated with ribosomal RNA transcription. During interphase, Ki-67 antigen is exclusively detected within the cell nucleus, whereas in mitosis, the majority of the protein relocates to the surface of the chromosomes. Quiescent or resting cells in the G~0~-phase do not express the Ki-67 antigen ([@b3-ol-06-05-1277]), making the Ki-67 antigen an excellent operational marker for determining the proliferation of a given cell population and the aggressiveness of malignancies ([@b4-ol-06-05-1277]). In experimental and clinical practice, Ki-67 and MIB-1 monoclonal antibodies are directed against different epitopes of the same proliferation-related antigen; whereas Ki-67 works only on frozen sections, MIB-1 may also be used on fixed sections ([@b5-ol-06-05-1277]).

The caspase-3 (CASP3) protein is a member of the cysteine-aspartic acid protease (caspase)/interleukin-1β-converting enzyme (ICE) family. CASP3 is activated directly by caspase-8, -9 and -10 in the apoptotic cell by extrinsic (death ligand) and intrinsic (mitochondrial) pathways to initiate apoptosis. CASP3 is synthesized as an inactive 32 kDa proenzyme and processed during apoptosis into its active form, which is composed of two subunits, p17--20 and p10--12. Activated CASP3 is responsible for the cleavage of poly(ADP-ribose) polymerase (PARP), actin and sterol regulatory element binding protein (SREBP), which are associated with apoptosis ([@b6-ol-06-05-1277]--[@b8-ol-06-05-1277]).

The p53 tumor suppressor gene is considered to be central in protecting against the development of cancer. The encoded protein is a master switch that coordinates and concentrates a plethora of stress signals, transforming them into a series of responses, including apoptosis or cell cycle arrest, in response to DNA damage, thereby maintaining genetic stability in the organism ([@b9-ol-06-05-1277]). Therefore, p53 has been described as 'the guardian of the genome' ([@b9-ol-06-05-1277],[@b10-ol-06-05-1277]). The p53 pathway is also involved in regulating metastasis-associated genes, including maspin, kai1, integrin, nm23, matrix metalloproteinase (MMP)-2, MMP-13 and the tissue inhibitor of metalloproteinase-3 (TIMP-3) ([@b10-ol-06-05-1277]--[@b16-ol-06-05-1277]). Although p53 inactivation in human cancer is a complex process that depends on the tissue type, p53 dysfunction may disorder the biological events of cancer cells, giving rise to their aggressive phenotypes.

Previously, we observed that p53 and Ki-67 were gradually increased from gastrointestinal mucosa to adenocarcinoma through adenoma. Accumulated p53 expression showed a positive association with the depth of invasion, local invasion via vessels and lymph node metastasis of gastrointestinal adenocarcinoma (GIA). Ki-67 expression was positively correlated with local invasion via vessels and negatively correlated with the dedifferentiation and liver metastasis of GIA ([@b17-ol-06-05-1277]). The present study investigated the clinicopathological and prognostic significance of Ki-67, CASP3 and p53 to clarify their roles in the regulation of the balance between proliferation and apoptosis.

Materials and methods
=====================

Patients
--------

This retrospective study was performed on curatively-resected gastric carcinoma specimens collected in Toyama University Hospital (Toyama, Japan) between 1993 and 2006. The patients with gastric carcinomas consisted of 130 males and 301 females (age range, 38--88 years; mean age, 66.4 years). Archival materials were obtained from the Department of Pathology. In 165 cases, tumor development was accompanied by lymph node metastasis. None of the patients underwent chemotherapy, radiotherapy and adjuvant treatment prior to surgery. All patients were followed up by consulting their case documents and by telephone.

Pathology
---------

All tissues were fixed in 10% neutralized formalin, embedded in paraffin and cut into 4-μm sections stained with hematoxylin and eosin (HE) to confirm the histological diagnosis and microscopic characteristics. The staging for each gastric carcinoma was evaluated according to the Union Internationale le Contre Cancer (UICC) system, indicating the extent of tumor spread ([@b17-ol-06-05-1277]). The histological architecture was defined in terms of Lauren's classification ([@b18-ol-06-05-1277],[@b19-ol-06-05-1277]). Furthermore, the tumor size, depth of invasion, lymphatic and venous invasion and lymph node metastasis of the tumors were determined.

Tissue microarray (TMA)
-----------------------

Representative areas of solid tumor were selected for sampling from HE-stained sections of the selected tumor cases, and 2-mm diameter tissue cores per donor block were punched out and transferred to a recipient block, with a maximum of 48 cores, using a Tissue Microarrayer (KIN-1; Azumaya, Tokyo, Japan). Sections (4-μm thick) were consecutively cut from the microarrays and transferred to poly-lysine-coated glass slides. HE staining was performed for the confirmation of the tumor tissue.

Immunohistochemistry
--------------------

Serial sections of TMA were deparaffinized with xylene, rehydrated with alcohol and subjected to immunohistochemical staining with intermittent microwave radiation, as previously described ([@b20-ol-06-05-1277]). Rabbit anti-human CASP3, rabbit anti-human Ki-67 (NovoCastra, Leica Biosystems Newcastle Ltd., Newcastle Upon Tyne, UK) and mouse anti-human p53 (Dako, Carpinteria, CA, USA) antibodies were used at 1:100 dilution to detect the respective proteins, with anti-rabbit or anti-mouse Envison-PO (Dako) as the secondary antibody. Binding was visualized with 3,3′-diaminobenzidine (DAB) and counterstaining with Mayer's hematoxylin was performed to aid orientation. Omission of the primary antibody was used as a negative control.

Immunoreactivity for Ki-67, p53 and CASP3
-----------------------------------------

In total, 100 cells from five representative fields of each section were randomly selected and counted in a blinded manner by two independent observers (L. Xiao and H.C. Zheng). Inconsistent data were discussed by the observers until final agreements were reached. The expression positivity was graded and counted as follows: 0, negative; 1, 1--50%; 2, 50--74%; and 3, ≥75%. The staining intensity score was graded as follows: 1, weak; 2, intermediate; and 3, strong. The scores for Ki-67, CASP3 and p53 positivity and staining intensity were multiplied to obtain a final score, which determined their expression as follows: −, 0; +, 1--2; ++, 3--4; and +++, 6--9.

Statistical analysis
--------------------

The statistical evaluation was performed using Spearman's correlation test to analyze rank data. Kaplan-Meier survival plots were generated and comparisons between survival curves were made with the log-rank statistic. Cox's proportional hazards model was used for the multivariate analysis. SPSS 17.0 software (SPSS Inc., Chicago, IL, USA) was applied to analyze all data and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Ki-67 and p53 positivity was clearly localized in the nuclei of the gastric cancer cells, while CASP3 was detected in the cytoplasm of the cancer cells ([Fig. 1](#f1-ol-06-05-1277){ref-type="fig"}). Ki-67 expression was positively correlated with tumor-node-metastasis (TNM) staging and p53 expression of gastric cancer (P\<0.05), but not with the patients' age or gender, tumor size, depth of invasion, lymphatic or venous invasion, lymph node metastasis or Lauren's classification (P\>0.05; [Table I](#tI-ol-06-05-1277){ref-type="table"}). CASP3 expression was positively correlated with Ki-67 expression in gastric carcinoma (P\<0.05), but not with the patients' age or gender, tumor size, depth of invasion, lymphatic or venous invasion, lymph node metastasis or TNM staging (P\>0.05). There was higher CASP3 expression in the intestinal-type compared with the diffuse-type of carcinoma (P\<0.05). The elder or male patients with gastric cancer showed higher p53 expression compared with the younger or female patients, respectively (P\<0.05; [Table II](#tII-ol-06-05-1277){ref-type="table"}). p53 expression was positively correlated with TNM staging and the CASP3 expression of gastric cancer (P\<0.05), but not with the tumor size, depth of invasion, lymphatic or venous invasion, or lymph node metastasis (P\>0.05). The intestinal-type carcinoma samples showed higher p53 expression compared with the diffuse-type samples (P\<0.05; [Table III](#tIII-ol-06-05-1277){ref-type="table"}).

Follow-up information was available for 499 of the gastric carcinoma patients for periods ranging between 0.2 months and 12.2 years (mean, 70.1 months). [Fig. 2](#f2-ol-06-05-1277){ref-type="fig"} shows survival curves stratified according to Ki-67, CASP3 and p53 expression. Univariate analyses using the Kaplan-Meier method indicated that there was a higher cumulative survival rate among carcinoma cases with negative CASP3 expression compared with weak, moderate and strong CASP3 expression (P\<0.05), whereas there was no correlation between Ki-67 or p53 expression and the survival rate of the patients with gastric cancer (P\>0.05). Cox's proportional hazard model indicated that the patient age, gender, depth of invasion, lymphatic invasion, lymph node metastasis, TNM staging, Lauren's classification and CASP3 expression, but not the tumor size, venous invasion and Ki-67 or p53 expression, were independent prognostic factors for gastric carcinomas (P\<0.05; [Table IV](#tIV-ol-06-05-1277){ref-type="table"}).

Discussion
==========

Cell proliferative activity is an important factor for assessing the biological behavior of carcinoma, and the identification of proliferating activities in tumors may be useful for predicting clinicopathological and prognostic significance. Ki-67 is a nuclear non-histone protein, which is required for maintaining the cell cycle ([@b22-ol-06-05-1277]). Our previous study showed gradually increasing expression of Ki-67 from the gastrointestinal mucosa to adenocarcinoma through adenoma ([@b17-ol-06-05-1277]). In the present study, it was observed that Ki-67 was expressed in 30.4% of gastric cancers and that Ki-67 expression was positively correlated with TNM staging and p53 expression, but not with aggressive parameters such as local invasion, lymph node metastasis and differentiation, which is consistent with previous studies ([@b23-ol-06-05-1277]--[@b27-ol-06-05-1277]). Xu *et al*([@b28-ol-06-05-1277]) noted that the expression of Ki-67 antigen was significantly associated with distant metastases to the liver, ovary and adrenal gland, but not to the histological type, growth pattern, depth of invasion, histological differentiation or the metastases to local lymph nodes. Several studies have reported that Ki-67 expression was a more valuable independent prognostic predictor for the survival of patients with gastric cancer ([@b24-ol-06-05-1277],[@b27-ol-06-05-1277],[@b29-ol-06-05-1277]), which is contrary to the present data.

Normal cells contain only a small amount of caspases in the form of inactive zymogens, and activated caspases have been transformed to proteases via the catalytic activity of enzymes capable of cleaving a number of substrate proteins, resulting in apoptosis. CASP3 is activated by a series of cascade reactions, until eventually DNase (CAD, CPAN or DEF40) is activated, which belongs to the Mg^2+^-dependent endonucleases, and acts as a killer in apoptosis ([@b6-ol-06-05-1277],[@b31-ol-06-05-1277]). Reportedly, CASP3 expression is higher in normal tissues compared with gastric carcinoma tissue ([@b6-ol-06-05-1277],[@b32-ol-06-05-1277]). Hoshi *et al*([@b32-ol-06-05-1277]) also observed that the positive rate of CASP3 expression was lower in gastric cancers compared with their adjacent mucosa and gastric adenoma. In the present study, there was higher CASP3 expression in intestinal-type compared with diffuse-type carcinoma, indicating that its aberrant expression underlies the molecular mechanisms of the differentiation of gastric cancer. Additionally, CASP3 was also demonstrated to correlate with the poor prognosis of patients with gastric cancer as an independent factor, in agreement with the study by Isobe *et al*([@b33-ol-06-05-1277]). The lack of correlation between CASP3 and aggressive behaviors of gastric cancer was consistent with our previous findings ([@b6-ol-06-05-1277]). Notably, the positive association between CASP3 and Ki-67 expression suggested the hypothesis that highly proliferating carcinomas may have a high apoptotic potential, contrary to results observed in a previous study ([@b32-ol-06-05-1277]).

The p53 gene is a tumor suppressor gene located on chromosome 17p13.1 and the single most common target for genetic alterations in human cancer, which is activated in response to genotoxic and non-genotoxic insults to cells ([@b34-ol-06-05-1277]). Mutated p53 lacks the DNA repair regulation of the cell cycle and results in metabolically stable abnormal protein that accumulates in the nucleus, which may be detected by immunohistochemistry ([@b35-ol-06-05-1277]). Our previous studies showed that aberrant p53 overexpression was more common in gastric carcinoma than adenoma ([@b17-ol-06-05-1277]) or intestinal metaplasia ([@b36-ol-06-05-1277]). In the present study, it was shown that p53 expression was positively correlated with the TNM staging and CASP3 expression of gastric cancer, and that expression was higher in intestinal-type compared with diffuse-type carcinomas, indicating that p53 expression may be involved in the progression and differentiation of gastric cancer. Gonçalves *et al*([@b35-ol-06-05-1277]) also noted that p53 expression was more frequent among gastric intestinal-type, differentiated and macroscopically elevated cancers. Significantly shorter survival times were observed in p53-negative patients compared with p53-positive patients. Tzanakis *et al*([@b37-ol-06-05-1277]) demonstrated that a more marked expression of p53 was associated with a tumor size of \>5 cm, and that advanced stage p53 expression was significantly decreased in poorly-differentiated adenocarcinoma compared with well- or moderately-differentiated adenocarcinoma, which is consistent with the present results. Unlike the present survival data, p53 overexpression was an independent adverse prognostic factor for survival ([@b37-ol-06-05-1277]).

In summary, the expression of Ki-67, CASP3 and p53 may be involved in the progression or differentiation of gastric carcinoma. These expression levels may be utilized as indicators of the pathobiological behaviors or prognosis of gastric carcinomas.
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###### 

Correlation between Ki-67 expression and clinicopathological features of gastric carcinomas.

  Clinicopathological features   n     Ki-67 expression, n   PR, %   P-value                
  ------------------------------ ----- --------------------- ------- --------- ----- ------ ---------
  Age, years                                                                                0.062
   \<65                          186   60                    28      36        62    67.7   
   ≥65                           245   55                    29      57        104   77.6   
  Gender                                                                                    0.539
   Female                        130   38                    14      26        52    70.8   
   Male                          301   77                    43      67        114   74.4   
  Tumor size, cm                                                                            0.146
   \<4                           222   66                    25      48        83    70.3   
   ≥4                            209   49                    32      45        83    76.6   
  Depth of invasion                                                                         0.380
   T~is-1~                       220   57                    28      48        87    74.1   
   T~2--4~                       211   58                    29      45        79    72.5   
  Lymphatic invasion                                                                        0.534
   −                             271   74                    33      60        104   72.7   
   +                             159   41                    24      33        61    74.2   
  Venous invasion                                                                           0.864
   −                             373   99                    52      86        136   73.5   
   +                             58    16                    5       7         30    72.4   
  Lymph node metastasis                                                                     0.566
   −                             262   72                    32      62        96    72.5   
   +                             165   43                    25      31        66    73.9   
  TNM staging                                                                               0.047
   0--I                          247   59                    32      58        98    76.1   
   II--IV                        184   56                    25      35        68    69.6   
  Lauren's classification                                                                   0.372
   Intestinal-type               214   50                    32      46        86    76.6   
   Diffuse-type                  203   62                    23      46        72    69.5   
  p53 expression                                                                            \<0.001
   −                             179   80                    31      36        32    55.3   
   +                             37    6                     9       8         14    83.8   
   ++                            66    7                     10      15        34    89.4   
   +++                           123   11                    4       31        77    91.1   

PR, positive rate; T~is~, carcinoma *in situ*; T~1~, lamina propria and submucosa; T~2~, muscularis propria and subserosa; T~3~, exposure to serosa; T~4~, invasion into serosa; TNM, tumor-node-metastasis.

###### 

Correlation between nuclear caspase-3 expression and clinicopathological features of gastric carcinomas.

  Clinicopathological features   n     CASP3 expression, n   PR, %   P-value               
  ------------------------------ ----- --------------------- ------- --------- ---- ------ ---------
  Age, years                                                                               0.100
   \<65                          173   75                    38      32        28   56.6   
   ≥65                           232   81                    56      42        53   65.1   
  Gender                                                                                   0.412
   Female                        125   54                    24      22        25   56.8   
   Male                          280   102                   70      52        56   63.6   
  Tumor size, cm                                                                           0.255
   \<4                           207   88                    51      31        37   57.5   
   ≥4                            198   68                    43      43        44   65.7   
  Depth of invasion                                                                        0.141
   T~is-1~                       205   88                    42      31        44   57.1   
   T~2--4~                       200   68                    52      43        37   66.0   
  Lymphatic invasion                                                                       0.447
   −                             254   101                   51      52        50   60.2   
   +                             150   55                    42      22        31   63.3   
  Venous invasion                                                                          0.537
   −                             347   132                   81      67        67   62.0   
   +                             58    24                    13      7         14   58.6   
  Lymph node metastasis                                                                    0.564
   −                             246   100                   55      40        51   59.3   
   +                             157   56                    39      34        28   64.3   
  TNM staging                                                                              0.919
   0--I                          232   91                    48      37        56   60.8   
   II--IV                        173   65                    46      37        25   62.4   
  Lauren's classification                                                                  \<0.001
   Intestinal-type               201   56                    51      36        58   72.1   
   Diffuse-type                  199   98                    43      35        23   50.8   
  Ki-67 expression                                                                         \<0.001
   −                             103   58                    28      14        3    43.7   
   +                             52    28                    8       9         7    46.2   
   ++                            87    29                    24      18        16   66.7   
   +++                           147   34                    29      30        54   76.9   

PR, positive rate; T~is~, carcinoma *in situ*; T~1~, lamina propria and submucosa; T~2~, muscularis propria and subserosa; T~3~, exposure to serosa; T~4~, invasion into serosa; TNM, tumor-node-metastasis; CASP3, caspase-3.

###### 

Relationship between p53 expression and clinicopathological features of gastric carcinomas.

  Clinicopathological features   n     p53 expression, n   PR, %   P-value                
  ------------------------------ ----- ------------------- ------- --------- ----- ------ ---------
  Age, years                                                                              0.032
   \<65                          175   90                  16      29        40    48.6   
   ≥65                           247   99                  22      38        88    59.9   
  Gender                                                                                  0.027
   Female                        127   65                  12      20        30    48.8   
   Male                          295   124                 26      47        98    58.0   
  Tumor size, cm                                                                          0.697
   \<4                           214   95                  20      35        64    55.6   
   ≥4                            208   94                  18      32        64    54.8   
  Depth of invasion                                                                       0.169
   T~is-1~                       215   89                  20      39        67    58.6   
   T~2--4~                       207   100                 18      28        61    51.7   
  Lymphatic invasion                                                                      0.861
   −                             264   119                 22      46        77    54.9   
   +                             157   70                  16      20        51    55.4   
  Venous invasion                                                                         0.721
   −                             362   160                 34      61        107   55.8   
   +                             60    29                  4       6         21    51.7   
  Lymph node metastasis                                                                   0.532
   −                             253   113                 21      45        74    55.3   
   +                             164   76                  16      21        51    53.7   
  TNM staging                                                                             0.047
   0--I                          241   98                  22      43        78    59.3   
   II--IV                        181   91                  16      24        50    49.7   
  Lauren's classification                                                                 \<0.001
   Intestinal-type               212   66                  22      42        82    68.9   
   Diffuse-type                  200   119                 13      24        44    40.5   
  CASP3 expression                                                                        0.004
   −                             142   95                  11      12        24    33.1   
   +                             90    42                  4       18        26    53.3   
   ++                            72    25                  8       13        26    65.3   
   +++                           81    12                  9       18        42    85.2   

PR, positive rate; T~is~, carcinoma *in situ*; T~1~, lamina propria and submucosa; T~2~, muscularis propria and subserosa; T~3~, exposure to serosa; T~4~, invasion into serosa; TNM, tumor-node-metastasis; CASP3, caspase-3.

###### 

Multivariate analysis of clinicopathological variables for the survival of the patients with gatric carcinomas.

  Clinicopathological parameters   Relative risk (95% CI)   P-value
  -------------------------------- ------------------------ ---------
  Age (≥65 years)                  1.962 (1.342--2.870)     0.001
  Gender (female)                  1.679 (1.079--2.612)     0.022
  Tumor size (\>4 cm)              1.511 (0.890--2.566)     0.126
  Depth of invasion (T~2--4~)      5.255 (2.376--11.622)    \<0.001
  Lymphatic invasion (+)           2.193 (1.421--3.383)     \<0.001
  Venous invasion (+)              1.158 (0.756--1.774)     0.500
  Lymph node metastasis (+)        3.629 (1.848--7.126)     \<0.001
  TNM staging (III--IV)            0.309 (0.138--0.694)     0.004
  Lauren's classification          2.251 (1.457--3.477)     \<0.001
  Ki-67 expression (+ to +++)      0.982 (0.822--1.172)     0.837
  CASP3 expression (+ to +++)      1.277 (1.064--1.533)     0.009
  p53 expression (+ to +++)        1.112 (0.947--1.306)     0.194

CI, confidence interval; TNM, tumor-node-metastasis; CASP3, caspase-3.
